Details for Patent: 10,953,003

Which drugs does patent 10,953,003 protect, and when does it expire?

Patent 10,953,003 protects XOLREMDI and is included in one NDA.

This patent has thirty-four patent family members in eleven countries.

Summary for Patent: 10,953,003

Title:	Methods for treating cancer
Abstract:	The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
Inventor(s):	Ragan Paula Marie, Arbeit Robert D., Crowley Kieran James
Assignee:
Application Number:	US16061974
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,953,003

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes			Y

International Family Members for US Patent 10,953,003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3008272
Canada	3008279
Canada	3009176
Canada	3010617